Physician

Jeffrey Mark Guardino, MD

According to 2025 Medicare claims, Jeffrey Guardino, MD (NPI: 1679537302) practices cardiology in the San Francisco-San Mateo-Redwood City, CA market, with the plurality of this provider's patient population coming from San Mateo, CA. This provider's primary affiliated billing organization is UNIVERSITY HEALTHCARE ALLIANCE (NPI: 1760531198; TIN: 943192446) and primary practice location at 94025-4260. Guardino is affiliated with the University Healthcare Alliance DBA Stanford Medicine Partners (ACO ID: A4733), participating under the MSSP model.

Guardino's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,137 traditional Medicare patients, billed 5,609 HCPCS/CPT codes, and received $615,616 in Medicare payments. The top billing code was 93241 (Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days). Part D data shows 6,531 prescription claims across 735 beneficiaries totaling $963,342 in drug costs, led by Eliquis (Apixaban). Open Payments data shows 3 records totaling $480. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $385,170 to $615,616. Similarly, Part D prescription costs have risen steadily, from $562,612 to $963,342. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	929	3,621	$385,170
2016	941	3,520	$383,554
2017	995	4,084	$411,894
2018	1,088	4,476	$419,159
2019	1,048	4,546	$469,522
2020	923	3,617	$339,371
2021	1,046	3,874	$491,940
2022	1,027	3,850	$494,581
2023	1,054	3,662	$559,546
2024	1,137	5,609	$615,616

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	576	6,932	$562,612
2016	551	6,473	$620,646
2017	555	6,352	$602,248
2018	567	6,260	$561,879
2019	557	5,987	$609,836
2020	565	5,933	$686,808
2021	594	6,079	$700,018
2022	680	6,365	$811,574
2023	717	6,293	$911,887
2024	735	6,531	$963,342

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93241	Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days	359	417	$269
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	699	714	$184
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	580	1,781	$160
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	582	1,778	$14
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	411	422	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	285	22,110	$435,015
Xarelto	Rivaroxaban	108	7,963	$149,658
Jardiance	Empagliflozin	36	2,700	$53,105
Farxiga	Dapagliflozin Propanediol	42	2,495	$46,051
Repatha Sureclick	Evolocumab	45	2,352	$45,368

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$480	Edwards Lifesciences Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeffrey Mark Guardino, MD?

Tedicare shows public-source Medicare data for Jeffrey Mark Guardino, MD (NPI 1679537302), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeffrey Mark Guardino, MD have ACO affiliation data?

Jeffrey Mark Guardino, MD is shown with ACO affiliation data for University Healthcare Alliance DBA Stanford Medicine Partners (MSSP, ACO ID A4733).

What billing organization is linked to Jeffrey Mark Guardino, MD?

Jeffrey Mark Guardino, MD is linked to UNIVERSITY HEALTHCARE ALLIANCE (billing NPI 1760531198) in the available physician profile data.

Does Jeffrey Mark Guardino, MD have Open Payments data?

Jeffrey Mark Guardino, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.